|
|
|
| A case report of SOX regimen combined with terriprizumab in treatment of intermediate and advanced combined hepatocellular-cholangiocarcinoma#br# |
| HE Yalin1 YANG Jiaxin1 CHENG Zhiqiang2 |
1.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Internal Oncology Integrated Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing 100029, China |
|
|
|
Abstract Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare type of primary hepatocellular carcinoma, which has differentiation characteristics of hepatocellular carcinoma and cholangiocarcinoma, it is considered an aggressive tumor with poor prognosis and little improvement in survival. For unresectable cHCC-CCA, the evidence of standard treatment is limited, and there are few reports about it at home and abroad. This paper reports a case of stage ⅢB cHCC-CCA who was unable to undergo radical resection at the time of diagnosis, after 15 cycles of SOX chemotherapy plus terriprizumab, finally, the diagnosis and treatment process of complete pathological remission was achieved. In order to improve the clinical diagnosis and treatment level of cHCC-CCA, retrospective case analysis and literature review.
|
|
|
|
|
|
[1] Wang AQ，Zheng YC，Du J，et al. Combined hepatocellular cholangiocarcinoma：Controversies to be addressed [J]. World J Gastroenterol，2016，22：4459-4465.
[2] Sempokuya T，Wien EA，Pattison RJ，et al. Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma [J]. World J Hepatol，2020，12（11）：1020-1030.
[3] Spolverato G，Bagante F，Tsilimigras D，et al. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma：A population-based analysis [J]. J Surg Oncol，2019，119（3）：278-287.
[4] Jung DH，Hwang S，Song GW，et al. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection [J]. Liver Transpl，2017，23（3）：330-341.
[5] Ramai D，Ofosu A，Lai JK，et al. Combined Hepatocellular Cholangiocarcinoma：A Population-Based Retrospective Study [J]. Am J Gastroenterol，2019，114（9）：1496-1501.
[6] Cong WM，Wu MC. New insights into molecular diagnostic pathology of primary liver cancer：Advances and challenges [J]. Cancer Lett，2015，368（1）：14-19.
[7] Wang J，Li E，Yang H，et al. Combined hepatocellular-cholangiocarcinoma：a population level analysis of incidence and mortality trends [J]. World J Surg Oncol，2019， 17（1）：43.
[8] Chen PD，Chen LJ，Chang YJ，et al. Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma：A Nationwide Study [J]. Oncologist，2021，26（10）：e1774-e1785.doi：10.1002/onco.13893
[9] Laohawetwanit T，Lerttanatum N，Wanpiyarat N，et al. Combined hepatocellular-cholangiocarcinoma and its mimickers：Diagnostic pitfalls in surgical pathology [J]. Ann Diagn Pathol，2021，53：151770.
[10] Chu KJ，Lu CD，Dong H，et al. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma：clinicopat-hological and prognostic analysis of 390 cases [J]. Eur J Gastroenterol Hepatol，2014，26（2）：192-199.
[11] Leoni S，Sansone V，Lorenzo SD，et al. Treatment of Combined Hepatocellular and Cholangiocarcinoma [J]. Cancers（Basel），2020，12（4）：794. DOI：10.3390/cancers12040794.
[12] Fowler K，Saad NE，Brunt E，et al. Biphenotypic primary liver carcinomas： assessing outcomes of hepatic directed therapy [J]. Ann Surg Oncol，2015，22（13）：4130-4137.
[13] Rogers JE，Bolonesi RM，Rashid A，et al. Systemic therapy for unresectable，mixed hepatocellular-cholangiocarcinoma：treatment of a rare malignancy [J]. J Gastrointest Oncol，2017，8（2）：347-351.
[14] Kobayashi S，Terashima T，Shiba S，et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma [J]. Cancer Sci，2018，109（9）：2549-2557.
[15] Finkelmeier F，Waidmann O，Trojan J. Nivolumab for the treatment of hepatocellular carcinoma [J]. Expert Rev Anticancer Ther，2018，18（12）：1169-1175.
[16] Rizell M，Aberg F，Perman M，et al. Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular Cholangiocarcinoma after Hepatic Resection [J]. Case Rep Oncol，2020，13（1）：478-484.
[17] Sheng XN，Yan XQ，Chi ZH，et al. Axitinib in Combination With Toripalimab，a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1，in Patients With Metastatic Mucosal Melanoma：An Open-Label Phase ⅠB Trial [J]. J Clin Oncol，2019，37（21）：2987-2999.
[18] Sheng X，Chen H，Yao X，et al. Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase Ⅱ clinical study [J]. J Clinical Oncology，2019，37(15_suppl)：4554-4554.
[19] Wang ZJ，Ying JM，Xu JC，et al. Safety，Antitumor Activity，and Pharmacokinetics of Toripalimab，a Programmed Cell Death 1 Inhibitor，in Patients With Advanced Non-Small Cell Lung Cancer：A Phase 1 Trial [J]. JAMA Netw Open，2020，3（10）：e2013770.
[20] Xing WQ，Zhao LD，Fu XM，et al. A phase Ⅱ，single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma [J]. J Thorac Dis，2020，12（11）：6861-6867.
[21] Benson AB，D’Angelica MI，Abbott DE，et al. Hepatobiliary Cancers，Version2.2021，NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2021，19（5）：541-565.
[22] Lee DW，Lee KH，Kim HJ，et al. A phase Ⅱ trial of S1 and oxaliplatin in patients with advanced hepatocellular carcinoma [J]. BMC Cancer，2018，18（1）：252.
[23] Brown JS，Sundar R，Lopez J. Combining DNA damaging the rapeutics with immunotherapy：more haste，less speed [J]. Br J Cancer，2018，118（3）：312-324.
[24] McGranahan N，Furness AJ，Rosenthal R，et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade [J]. Science，2016，351（6280）：1463.
[25] Ang C，Klempner SJ，Ali SM，et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma [J]. Oncotarget，2019，10（40）：4018-4025.
[26] Zhu AX，Finn RS，Edeline J，et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib （KEYNOTE-224）：a non-randomised，open-label phase 2 trial [J]. Lancet Oncol，2018，19（7）：940-952.
|
|
|
|
